MedTrace Logo

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

NCT01511029 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2014-11-25

No results posted yet for this study

Summary

To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.

Conditions

Interventions

DRUG

Dexpramipexole

300 mg - Oral Tablets

DRUG

Dexpramipexole

600 mg Oral Tablets

DRUG

Dexpramipexole Placebo

Placebo - Oral Tablet

DRUG

Moxifloxacin

400 mg - Oral Tablet

Sponsors & Collaborators

  • Knopp Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511029 on ClinicalTrials.gov